Intercept Announces FDA Acceptance of Supplemental New Drug

sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as...

Related Keywords

Paul Nitschmann , Advisory Committee , Linkedin , Regulatory Affairs At Intercept , Drug Administration , Globenewswire Inc , Twitter , International Normalized Ratio , Intercept Pharmaceuticals Inc , New Drug Application , Prescription Drug User Fee Act , Senior Vice President , Regulatory Affairs , Narrow Therapeutic , Bile Salt Efflux , Full Prescribing Information , Intercept Pharmaceuticals ,